Last $1.73 USD
Change Today +0.04 / 2.37%
Volume 1.3M
PPHM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (PPHM) Snapshot

Open
$1.69
Previous Close
$1.69
Day High
$1.74
Day Low
$1.65
52 Week High
03/6/14 - $3.18
52 Week Low
06/27/13 - $1.11
Market Cap
305.3M
Average Volume 10 Days
2.8M
EPS TTM
$-0.22
Shares Outstanding
176.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PEREGRINE PHARMACEUTICALS (PPHM)

peregrine pharmaceuticals (PPHM) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (PPHM) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer. The company’s lead product candidates in development include Bavituximab, a phosphatidylserine (PS) targeting agent that completed Phase IIb second-line non-small cell lung cancer trial for the treatment of solid tumors; and Cotara, a DNA/histone-targeting antibody that completed Phase II multicenter trial for the treatment of brain cancer. It is also conducting various other trials with bavituximab in combination with other therapies in multiple oncology indications as potential secondary indications for bavituximab; and an open-label single-center clinical trial under an exploratory investigational new drug application filed with the FDA for its lead imaging agent 124I-PGN650 for the imaging of multiple solid tumor types. In addition, the company, through its subsidiary, Avid Bioservices, Inc., provides various contract biomanufacturing services that support the development and current good manufacturing practices (cGMP) production of clinical and commercial monoclonal antibodies, and recombinant proteins and enzymes, including cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has license, research, and development agreements with the University of Texas Southwestern Medical Center; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; UTSWMC; and Merck KGaA. The company was founded in 1981 and is based in Tustin, California.

182 Employees
Last Reported Date: 07/11/13
Founded in 1981

peregrine pharmaceuticals (PPHM) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $445.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $338.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $252.0K
Vice President of Intellectual Property
Total Annual Compensation: $291.5K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $270.2K
Compensation as of Fiscal Year 2013.

peregrine pharmaceuticals (PPHM) Key Developments

Peregrine Presents its PS-Targeting Immunotherapy Agent Bavituximab with Irradiation in Lung Cancer

Peregrine Pharmaceuticals, Inc. announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy (SBRT) showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer (NSCLC) compared to irradiation alone. These data were presented at the 105(th) Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial. These studies utilized rats bearing established orthotopic A549-luc NSCLC tumors, which were staged and monitored by bioluminescence imaging. Animals were treated with 3x12 Gy of radiation alone or combined with 2aG4 (mouse equivalent antibody to bavituximab) injected twice weekly. Rats treated with radiation and 2aG4 had a 100% survival rate 184 days after implantation and tumors were completely eradicated in 67% of these animals. In contrast, rats treated with radiation had a survival rate of 43% while only 12.5% of untreated rats survived. A toxicity study was conducted in which 3x12 Gy of radiation was delivered to central organs of tumor-free rats. This treatment does not appear to cause severe toxicity. These results suggest that bavituximab with radiation may result in improved clinical outcome in patients with centrally-located NSCLC.

Peregrine Pharmaceuticals, Inc. Presents at BIO Asia International Conference, Apr-08-2014 03:30 PM

Peregrine Pharmaceuticals, Inc. Presents at BIO Asia International Conference, Apr-08-2014 03:30 PM. Venue: Grand Hyatt, Tokyo, Tokyo, Japan. Speakers: Stephen Worsley, VP, Business Development.

Peregrine Pharmaceuticals, Inc. Announces Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' Ps-Targeting Antibodies

Peregrine Pharmaceuticals, Inc. announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial. In a poster titled, 'Phosphatidylserine-Targeting Antibody Triggers -Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a Potent Inhibitor of HIV-1 In Vitro', Cyril Empig, Ph.D., associate director of preclinical research in infectious disease at Peregrine, presented data from studies conducted by Duke University and Peregrine researchers that further characterizes the mechanism by which the PS-binding antibody PGN632 inhibits the HIV infection of cells. Results revealed that PGN632 stimulates immune cells to link together and secrete molecules that block viral receptors used by HIV to infect cells. Furthermore, the immune-stimulatory mechanism of PS-targeting antibodies was further validated as study results showed that the antiviral mechanism of action was dependent on using the full length antibody rather than an antibody fragment that simply blocks PS. In an oral presentation titled, 'Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor-Specific Immunity' Xianming Huang, Ph.D., of The University of Texas Southwestern Medical Center in Dallas, presented data from studies demonstrating that PS-targeting antibodies override PS-mediated immune suppression in tumors and induce multiple downstream immune-stimulatory effects. Results showed a reduction of highly immunosuppressive myeloid derived suppressor cells (MDSC), increases in inflammatory cytokines, tumor-fighting M1 macrophages, mature dendritic cells and tumor-specific cytotoxic T-cells. Additionally, combination therapy studies utilizing a PS-targeting antibody with an anti-PD-1 antibody yielded enhanced therapeutic results in a preclinical model of melanoma, including delays and reductions in tumor growth compared to either antibody administered alone. Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but 'flips' and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor. These data detailing the immune-stimulatory mechanism of action of PS-targeting antibodies, such as the company's lead drug candidate bavituximab, are the subject of a manuscript published in the October 2013 issue of the American Association for Cancer Research (AACR) peer-reviewed journal, Cancer Immunology Research. Keystone Symposia serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PPHM:US $1.73 USD +0.04

PPHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PPHM.
View Industry Companies
 

Industry Analysis

PPHM

Industry Average

Valuation PPHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit www.peregrineinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.